Abstract 1434P
Background
The spatial architecture of B and T cells in the tumor microenvironment (TME) is known to be associated with treatment response in cancer patients. However, more complex spatial statistics to characterize the interaction of more than two immune cell types could further inform our understanding of tumor response to immunotherapy (IO). In this work we sought to evaluate quantitative metrics of higher order spatial relationships between multiple (>2) cell types to better characterize and predict overall survival (OS) in NSCLC patients.
Methods
The study included quantitative immunofluorescence images of pre-IO tumor biopsy specimen of 135 NSCLC patients from five centers with OS information. To predict OS, a set of 223 image features that characterize the spatial interplay of different cell types (CD4+, CD20+, CD8+, tumor, and stroma) in the TME were extracted. First, every nucleus belonging to each immune cell family was detected using an image analysis program (MATLAB) to identify the cell’s expression, subsequently the cell coordinates were recorded. The algorithm then identifies each triplet of distinct cells in proximity of each other to form spatial triangles. Features relating to the density, neighborhood, and proximity of nuclei were subsequently extracted. A risk score (RS) was then computed for each patient using the least absolute shrinkage and selection operator. To predict OS, the Cox regression model was trained on 100 patients (St) and validated on 35 patients (Sv). The discriminative ability of the features was assessed using Kaplan-Meier and log-rank tests.
Results
The RS was significantly associated with OS in both St (HR: 1.76; 95% CI = 1.09 - 2.85; P = .02), and Sv (HR: 2.8; 95% CI= 1.18–6.68; P=.01). RS based risk stratification showed greater accumulation of tumor, CD4 T cells, and CD20 B cells in very close proximity of each other in low-risk patients, compared to high-risk patients.
Conclusions
Machine learning derived features describing the higher order spatial relationships between tumor, CD20 B cells, and CD4 T cells were found to be associated with OS in NSCLC patients treated with IO. Additional, independent multi-site validation of these findings is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Schalper: Financial Interests, Speaker, Consultant, Advisor: Agenus, Ariagen, AstraZeneca, Bristol Myers Squibb , Clinica Alemana de Santiago, Genmab, Merck Sharp and Dohme, OnCusp Therapeutics, Repertoir Therapeutics, Takeda Oncology; Financial Interests, Institutional, Research Grant: Akoya Biosciences, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb , Eli Lilly and Company , Merck Sharp and Dohme, Navigate Biopharma, Pierre-Fabre, Ribon Therapeutics, Surface Oncology, Takeda Oncology, Tesaro, Inc.; Financial Interests, Advisory Board: EMD Serono, Shattuck Labs; Financial Interests, Research Grant: Moderna Inc. A. Madabhushi: Financial Interests, Personal, Advisory Board, Serve on SAB and consult: SimbioSys; Financial Interests, Personal, Advisory Board: Aiforia, Picture Health; Financial Interests, Personal, Full or part-time Employment: Picture Health; Financial Interests, Personal, Ownership Interest: Picture Health, Elucid Bioimaging, Inspirata Inc; Financial Interests, Personal, Royalties: Picture Health, Elucid Bioimaging; Financial Interests, Institutional, Funding: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
1379P - Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations
Presenter: Jin-Ji Yang
Session: Poster session 20
1380P - Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial
Presenter: Santiago Viteri
Session: Poster session 20
1381P - TOGETHER: Pooled real-world datasets of METex14 skipping NSCLC and adjusted comparison of upfront (chemo-)immunotherapy with tepotinib from VISION
Presenter: Petros Christopoulos
Session: Poster session 20
1382P - Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib
Presenter: Christian Rolfo
Session: Poster session 20
1383P - Efficacy of capmatinib compared to standard of care for German patients with locally advanced or metastatic NSCLC harboring METex14 mutations: Results from the RECAP study
Presenter: Anna Kron
Session: Poster session 20
1384P - Phase II study of cabozantinib in patients with MET-altered lung cancers
Presenter: Guilherme Harada
Session: Poster session 20
1385P - Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers
Presenter: Monica Chen
Session: Poster session 20
1386P - Validation of MET amplification using next-generation sequencing in lung adenocarcinoma
Presenter: Marta Salido
Session: Poster session 20
1387P - Efficacy of first-line treatment options in advanced HER2-altered non-small cell lung cancer: A multi-center retrospective study
Presenter: haifeng sun
Session: Poster session 20
1388P - Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC)
Presenter: Shirish Gadgeel
Session: Poster session 20